Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by GrahamBon Aug 07, 2021 1:59pm
203 Views
Post# 33668529

RE:Remote training and installation

RE:Remote training and installation
Jennifer2020 wrote: I expect the "good news" alluded to in the mgmt email about the AGM is sales.  This is the email that got things rolling from the low of .295

In fact, the company has already gained early sales traction with 16 sites completed the placements and 11 sites in progress. The Hospital committed placements breakdown is as per follows:

  • Canada – 5 sites completed/2 additional sites in process
  • US – 1 site completed/4 additional sites in process
  • UK – 1 site completed and 3 sites in process
  • Europe – 1 site completed/2 sites in process
  • China – 8 sites completed

Last but not least, it is anticipated that multiple units will be purchased regularly by each hospital that uses the VMS+3.0 system – further boosting the growth ahead.

https://www.smallcapasia.com/5-things-to-like-about-ventripoint/




Jennifer, I hear you, but to me - I will wait for factual evidence that such sales are hitting the bottoms line(esp re China where the terms of any such sales are difficult to understand for a simple guy like me)

I have posted on the lack of evidence for meaningful sales and repost below.

 

Still,
If there are sales they must be reported on the financials.

Yet, as noted…. 

 

We hear so much about potential sales, China, etc. yet the recent financials showed zero sales

 

In fact the sales have been declining yoy

 

The numbers that I had, (in reference to above)and correct me if I’m wrong are:

 

Ventripoint 

Operating expenses for the last 3 months 889,452

Revenue was Zero

Total loss for the period; 1,433,551

 

Weighted average number of common shares outstanding 118,806,636

 

 

Year Ended December 31, 2020

 

 Revenue 36,017

Cost of Sales (9,747) 

Gross Margin 26,270

 

Total loss and comprehensive loss for the year (1,811,086)

 

Weighted average number of common shares outstanding 74,515,947

 

Year Ended December 31, 2019

 

Revenue 81,023

Cost of Sales (43,852)

Gross Margin 37,171

 

Total loss and comprehensive loss for the year (3,322,628) 

 

Weighted average number of common shares outstanding 63,374,776 

 

 

Source:SEDAR.com



<< Previous
Bullboard Posts
Next >>